GlassScriptPhysician profile
Alvin Greengart
NPI 1427007947
$1,078.41
in general payments reported to CMS, 2019-2025
11 companies · $22.58 in 2025
The $22.58 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $186 · 2021: $238 · 2022: $218 · 2025: $22.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $343.74 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $167.12 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $146.61 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $113.79 | 2019 | |
| Amgen INC. | $97.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.13 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $50.25 | 2019-2021 | |
| Irhythm Technologies, INC. | $37.62 | 2019 | |
| Glaxosmithkline, LLC. | $22.58 | 2025 | Nucala |
| Lantheus Medical Imaging, INC. | $21.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvin Greengart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.